- Why a nursing home staff mandate will hurt patients.
- Trends in health care: private equity, M & A and digital health.
- Cato study: charter schools improve reading scores and reduce absenteeism at traditional public schools.
- How to increase US economic growth and why that matters.
- Biden has raised more money from tariffs than Trump did.
Category: Public Insurance
Thursday Links
- 50 years of US industrial policy. For those of you who think it is something new.
- Getting the priorities right: The Senate Budget Committee this session has held a total of 29 hearings, 15 of which were on climate and just 3 on the budget.
- Burgess: Under a “warranty approach” drug companies would refund a pre-negotiated amount of the drug’s price to the payor and patient if the latter’s health does not improve as expected. Under a “cost sharing approach,” the high upfront cost of gene therapy would be shared by subsequent insurers after the treatment succeeds.
- 10,000 commandments: Federal regulatory burdens cost $1.94 trillion per year, or $14,500 per household.
- Argument: drug shortages are caused by monopolistic middlemen. (Surely not the whole of the story.)
Could Racial Health Disparities All Be in Our Genes?
According to the Centers for Disease and Prevention (CDC) racism has caused a pronounced negative impact on the health of minorities and communities of color. Many sociologists and public health experts blame racism and the resulting so-called social determinants of health for lower health status among black Americans. The social determinants of health are a big area of research nowadays.
Accelerated Approval Benefits Patients with Some Caveats
Nowadays more than four-in-five drugs granted accelerated approval are oncology drugs (85%). How well is it working? That depends. The program to grant patients early access to promising new drugs does just that: it is used a lot. Since it began in 1992, 290 drugs have been approved through the accelerated program. That works out to more than nine a year, on average, or nearly one a month. By any measure that accelerated access to new drugs.